Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

NCT03657160 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

343

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematopoietic Stem Cells

Interventions

DRUG: Vedolizumab Placebo
DRUG: Vedolizumab

Sponsor

Millennium Pharmaceuticals, Inc.